AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change
A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early s
Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl